Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 4:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2185–2208 of 13,615 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatoses Clear all

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions: Behavioral Assessment, Electronic Health Record Review; Behavioral · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Scar, Breast Neoplasms, Breast Diseases, Surgical Wound
Interventions: Steri-strip; Device
Lead sponsor: Albert Einstein Healthcare Network; Other
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: East Norriton, Pennsylvania • Philadelphia, Pennsylvania

Conditions: Menkes Disease
Interventions: Long Term Follow-Up; Drug
Lead sponsor: Sentynl Therapeutics, Inc.; Industry
Eligibility: Not listed
Enrollment: 50 participants
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Solana Beach, California

Conditions: Skin Laxity
Interventions: Ulthera® System, Sculptra®, Sculptra® treatment followed by Ultherapy™ treatment; Device · Drug · Other
Lead sponsor: Ulthera, Inc; Industry
Eligibility: 35 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Psoriasis, Cardiovascular Disease
Interventions: Adalimumab (Humira), Placebo Injection, NB-UVB phototherapy; Drug · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 9
States / cities: Sacramento, California • Denver, Colorado • Bethesda, Maryland + 6 more

Conditions: Diabetic Foot Ulcer
Interventions: Alert for temperature delta; Device
Lead sponsor: DAPS Health LLC; Other
Eligibility: 35 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Annapolis, Maryland

Conditions: Breast Cancer
Interventions: 12 month exercise and weight loss intervention; Behavioral
Lead sponsor: University of Vermont; Other
Eligibility: 21 Years to 69 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Breast Cancer
Interventions: Stereotactic radiotherapy delivered by CyberKnife, stereotactic radiotherapy; Radiation
Lead sponsor: Essentia Health; Other
Eligibility: 60 Years to 60 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2025
U.S. locations: 1
States / cities: Duluth, Minnesota

Conditions: Moderate-to-severe Chronic Plaque Psoriasis
Interventions: Ponesimod; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 10
States / cities: Glendale, Arizona • Fremont, California • Miami, Florida + 7 more

Conditions: Cutaneous T-cell Lymphoma, Sezary Syndrome, Mycosis Fungoides, Eczema, Atopic Dermatitis
Interventions: Blood draw, skin biopsy or urine collection; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2032
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Breast Cancer
Interventions: Fulvestrant, Alpelisib, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 34
States / cities: Chandler, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 31 more

Conditions: Skin Laxity
Interventions: Dermal Cooling System; Device
Lead sponsor: R2 Dermatology; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Folsom, California • Fremont, California

Conditions: Melanoma, Colon Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Hepatocellular Cancer
Interventions: National Cancer Institute (NCI)-4650, a messenger ribonucleic acid (mRNA)-based, Personalized Cancer Vaccine; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cancer
Interventions: graft versus host disease prophylaxis/therapy, allogeneic bone marrow transplantation; Biological · Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: Up to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2004
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Rosacea
Interventions: brimonidine topical gel 0.33% & survey, brimonidine topical gel 0.33% & SOC; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Intraocular Melanoma, Melanoma (Skin)
Interventions: temozolomide, thalidomide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: New York, New York

Conditions: Neurodermatitis
Interventions: Dupilumab SAR231893, Placebo, Moisturizers, Low to medium potent topical corticosteroids, Topical calcineurin inhibitors; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 21
States / cities: Gilbert, Arizona • Fort Smith, Arkansas • Sacramento, California + 18 more

Conditions: Breast Cancer, Gut Microbiome, Exercise, Fatigue
Interventions: Aerobic Exercise Training, Attention Control; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 74 Years · Female only
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Breast Cancer, Diabetes Type II
Interventions: Inavolisib, Fulvestrant, Palbociclib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 9
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Grand Island, Nebraska + 4 more

Conditions: Node-positive Breast Cancer
Interventions: Hypofractionated radiation, Ultra-hypofractionated breast/chest wall and regional nodal radiation; Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Actinic Keratosis (AK)
Interventions: RLS-1496 1.0% cream; Drug
Lead sponsor: Rubedo Life Sciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 4
States / cities: Hot Springs, Arkansas • New Brighton, Minnesota • Omaha, Nebraska + 1 more

Conditions: Acne Scarring
Interventions: Fractionated Laser Resurfacing; Procedure
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 59 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Breast Cancer, Gynecologic Cancer, Sexual Dysfunction, Partner Communication
Interventions: Self-Guided PEPP Intervention Workbook, Self-Guided PEPP Education Workbook; Behavioral
Lead sponsor: The University of Tennessee, Knoxville; Other
Eligibility: 18 Years to 99 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions: One Diet and Physical Activity Session, Electronic (e) Health (eHealth) Communication Intervention, Twelve Diet and Physical Activity Group Sessions, Questionnaire Administration, Quality-of-Life Assessment; Behavioral · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

Precision Performance Status Assessment in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

Aesthetic Effect of Steri-Strip Orientation on Healing and Scar Appearance in Breast Surgery

Long Term Follow-up on Menkes Disease Patients

Ultherapy™ Treatment Following Sculptra® Treatment

Vascular Inflammation in Psoriasis Trial (The VIP Trial)

A Predictive Technology for Prevention of Diabetic Foot Ulcers

Behavioral Weight Loss and Exercise After Treatment (BEAT)

Conformal Partial Breast Irradiation With CyberKnife After Resection for Early Stage Breast Cancer

Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis

Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.

Dermal Cryotherapy in Patients Undergoing Abdominoplasty

Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer

Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

Internet Surveys and Their Impact on Adherence for Rosacea

Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)

Gut Microbe Composition, Exercise, and Breast Breast Cancer Survivors

A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes

Ultra-Hypofractionated vs. Hypofractionated Radiation for Node-Positive Breast Cancer

Evaluate RLS-1496 Topical Cream for Actinic Keratosis

Safety and Efficacy of 1550nm Fractional Laser Treatment for Acne Scars in Fitzpatrick Type IV-VI Skin

Psychosexual Educational Partners Program (PEPP)

Lifestyle Program (Scalable Nutrition and Physical Activity) for the Improvement of Nutrition and Physical Activity in Stage 0-III Breast Cancer Survivors